Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

This study is currently recruiting participants.
Verified June 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00246857
First received: October 29, 2005
Last updated: March 14, 2014
Last verified: June 2013
  Purpose

This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system in the cell growth and cell death processes that regulate lymphocyte homeostasis.

Patients who have, or are suspected of having, an inherited lymphocyte homeostasis or programmed cell death susceptibility syndrome may be eligible for this study. Relatives of patients are also included.

Participants' (patients and relatives) medical records are reviewed and blood samples are drawn for studies to identify genes involved in immune disorders. Tissues that have been removed from patients for medical reasons, such as biopsied tissues, may be examined for tissue and DNA studies. Relatives are studied to determine if some of them may have a very mild form of lymphocyte homeostasis disorder.

Patients who have an immune problem that the researchers wish to study further will be invited to donate additional blood samples at irregular intervals (at least once a year) and to provide an update of their medical records at the same time.


Condition
Lymphocyte Homeostasis
Genetic Diseases

Study Type: Observational
Official Title: Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 1000
Study Start Date: October 2005
Detailed Description:

This protocol is designed to screen patients with suspected or identified genetic diseases of lymphocyte homeostasis and programmed cell death. Patients determined by clinical history and initial outside evaluation by their referring physician to be of interest will be consented and enrolled into this study. Blood specimens from such patients or their family members will be obtained for research studies related to understanding the genetic and biochemical bases of these diseases. Outside medical records will be obtained for chart review to correlate clinical history to research laboratory testing results. Results will be relayed to the referring physicians and where applicable patients will be referred to other appropriate NIH protocols for additional clinical evaluation and treatment. The study will enroll up to 500 patients and family members over the next 5 years.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Patients known to have or suspected of having an inherited lymphocyte homeostasis or programmed cell death susceptibility syndrome will be eligible for enrollment. In the latter case, because of the intensive time and labor required for research laboratory testing, patients will be enrolled only if in the opinion of the investigator there is a high index of suspicion.

Blood relatives of enrolled patients will be eligible for enrollment.

There will be no limit as to age, sex, race or disability.

EXCLUSION CRITERIA:

The presence of an acquired abnormality, such as HIV, cytotoxic chemotherapy, or malignancy may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process interfered with evaluation.

Severely debilitated health status or poor venous access may also preclude obtaining adequate specimens for analysis.

Within the limits of maximal acceptable blood draw volumes and minimum requirement for core laboratory tests (9 ml of blood for V.A.2a and b), the cutoff weight for infants permitted in this protocol is 3 kg and above.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00246857

Contacts
Contact: Helen F Matthews (301) 443-8080 matthewsh@mail.nih.gov
Contact: Michael J Lenardo, M.D. (301) 496-6754 mlenardo@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229-3039
Turkey
Hacettepe University Recruiting
Ankara, Turkey
Sponsors and Collaborators
Investigators
Principal Investigator: Michael J Lenardo, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
  More Information